A Single-Dose Open-Label Study of XOMA 358 in Subjects With Congenital Hyperinsulinism
Status:
Completed
Trial end date:
2017-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and clinical pharmacology of a single
dose pharmacokinetics and pharmacodynamics of XOMA 358 in subjects with hypoglycemia
associated with congenital hyperinsulinism.